{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(3)"],"submitter":["Kaneko S"],"pubmed_abstract":["<h4>Background</h4>Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA-II is unclear. This prospective study aimed to verify Elecsys PIVKA-II compared with Lumipulse PIVKA-II in a cohort with advanced HCC undergoing systemic therapy.<h4>Methods</h4>A total of 62 HCC patients who were treated with atezolizumab and bevacizumab (ATZ+BEV) and molecular targeted agents (MTAs) were prospectively enrolled at Musashino Red Cross Hospital from January 2020 to December 2020. A total of 208 serum samples from 52 patients were tested using Elecsys PIVKA-II and Lumipulse PIVKA-II assays. Furthermore, the relationsh"],"journal":["PloS one"],"pagination":["e0265235"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8912231"],"repository":["biostudies-literature"],"pubmed_title":["Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma."],"pmcid":["PMC8912231"],"pubmed_authors":["Tsuchiya K","Takaura K","Yasui Y","Kirino S","Nobusawa T","Inada K","Higuchi M","Maeyashiki C","Tamaki N","Kurosaki M","Kaneko S","Takahashi Y","Tanaka Y","Tanaka S","Matsumoto H","Nakanishi H","Izumi N","Ishido S","Yamashita K","Kakegawa T","Hayakawa Y"],"additional_accession":[]},"is_claimable":false,"name":"Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.","description":"<h4>Background</h4>Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA-II is unclear. This prospective study aimed to verify Elecsys PIVKA-II compared with Lumipulse PIVKA-II in a cohort with advanced HCC undergoing systemic therapy.<h4>Methods</h4>A total of 62 HCC patients who were treated with atezolizumab and bevacizumab (ATZ+BEV) and molecular targeted agents (MTAs) were prospectively enrolled at Musashino Red Cross Hospital from January 2020 to December 2020. A total of 208 serum samples from 52 patients were tested using Elecsys PIVKA-II and Lumipulse PIVKA-II assays. Furthermore, the relationsh","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-19T00:39:16.314Z","creation":"2025-04-07T11:43:33.766Z"},"accession":"S-EPMC8912231","cross_references":{"pubmed":["35271670"],"doi":["10.1371/journal.pone.0265235"]}}